KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.

Scott D Lee, Adam C Ehrlich, Paola Pellanda, Christopher Kaiser, Kristin Todd, Richard Moses, Alissa Walsh

Am J Gastroenterol 120(12) 2857-2866

PMID40071779
PMCIDPMC12662148
DOI10.14309/ajg.0000000000003407
发表日期2025-03-12
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

INTRODUCTION: Ulcerative colitis (UC) is a chronic immune-mediated disease requiring ongoing treatment to maintain remission. This report presents the 2-year safety outcomes of mirikizumab, a humanized immunoglobulin G4 anti-interleukin-23p19 monoclonal antibody, in moderately to severely active UC from phase 3 studies LUCENT-1 (NCT03518086), LUCENT-2 (NCT03524092), and LUCENT-3 (NCT03519945). METHODS: Patients who underwent induction (LUCENT-1) and maintenance (LUCENT-2), and entered long-term maintenance (LUCENT-3) were assessed in 2 cohorts: induction responders and extended-induction responders. Both cohorts underwent up to 104 weeks of continuous treatment with mirikizumab. Adverse events (AEs) were assessed in these 2 cohorts and within subsets of patients aged 60 years or older and patients using corticosteroids, immunomodulators, or both at baseline. RESULTS: Safety was generally consistent across induction responders (N = 333) and extended-induction responders (N = 149) and across patient subsets. Nasopharyngitis, COVID-19, arthralgia, UC (worsening/reoccurrence of symptoms), and headache were the most common AEs. Serious AEs were reported in less than 10% of both cohorts. Infections (mostly mild), cerebrocardiovascular events, and malignancies occurred in 47.4% and 49.7%, 0.9% and 1.3%, and 0% and 3.4% of induction responders and extended-induction responders, respectively. Injection-site reactions (induction responders: 10.2% and extended-induction responders: 8.1%) declined over time. Safety profiles in patient subsets and in the whole population were similar, except for hypertension, which was more frequent in patients aged 60 years or older. DISCUSSION: The mirikizumab 2-year integrated safety profile in patients with moderately to severely active UC was consistent across subgroups and with previous findings, without new significant safety concerns.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. IR 100 of patients reporting opportunistic infections by study period. One InR patient reported a case of oral candidiasis during the maintenance period and a second case during the extension; this patient was counted in both periods. EInR, extended-induction responder; InR, induction responder; IR 100 =incidence rate per 100 patient-years; W, Week.
非 KM Figure
Figure 2Figure 2. Injection-site reaction over time following subcutaneous mirikizumab injection during maintenance. ( a ) Percentages of InRs and EInRs reporting at least one injection-site reaction throughout LUCENT-2 and LUCENT-3. ( b ) Percentages of InRs and EInRs reporting new injection-site reaction events throughout LUCENT-2 and LUCENT-3. Time intervals are based on time on mirikizumab only. No SC injections were administered prior to Week 12 for InRs and prior to Week 24 for EInRs. EInR, extended-induction responder; InR, induction responder; ISR, injection-site reaction.
非 KM Figure